Cytokine profile in chronic cardiac failure

European Journal of Clinical Investigation

Volumn 26, Issue 11, 1996, Pages 1018-1022

  Steele, I C ^a   Nugent, A M ^a   Maguire, S ^a   Hoper, M ^a   Campbell, G ^a   Halliday, M I ^a   Nicholls, D P ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

Chronic cardiac failure; Interleukin 6; Interleukin 8; Tumour necrosis factor; Tumour necrosis factor receptor

Indexed keywords

CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CACHEXIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEART FAILURE; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL;

EID: 0029854158     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1996.2560587.x     Document Type: Article

References (28)

1. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41.
2. McMurray J, Abdullah I, Dargie HJ, Shapiro D. Increased concentrations of tumour necrosis factor in 'cachectic' patients with severe chronic heart failure. Br Heart J 1991;66:356-8.
3. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993;92:2303-12.
4. Katz SD, Rao R, Berman JW et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure: relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation 1994;90:12-16.
5. Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. Tumour necrosis factor α in severe chronic congestive cardiac failure. Br Heart J 1993;70:141-3.
6. Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987;47:2986-9.
7. Tartaglia L, Goeddel D. Two TNF receptors, Immunol Today 1992;13:151-3.
8. Engelmann H, Novick D, Wallach W. Two tumor necrosis factor-binding proteins purified from human urine: evidence for cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990;265:1531-6.
9. Seckinger P, Isaaz S, Dayer JM. Purification and biological characterization of a specific tumor necrosis factor α inhibitor. J Biol Chem 1989;264:11966-73.
10. Gardiner KR, Halliday MI, Barclay GR et al. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 1995;36:897-901.
11. Matsumori S, Yamada T, Matoba Y, Sasayama S. Tumor necrosis factor in cardiomyopathy and myocarditis (abstract). Circulation 1992;86:I-439.
12. Pritchett G, Cohen HJ, Rao KMK, Cobb F, Sullivan M, Currie MS. Tumor necrosis factor, natural killer activity and other measures of immune function and inflammation in elderly men with heart failure. Gerontology 1995;41:45-6.
13. Finkel MS, Hoffman RA, Shen L, Oddis CV, Simmons RL, Hatler BG. Interleukin-6 (IL-6) as a mediator of stunned myocardium. Am J Cardiol 1993;71:1231-2.
14. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler GB, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-9.
15. Suffredini AF, Fromm RE, Parker MM et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989;321:280-7.
16. Pagani FD, Baker LS, Hsi C, Knox M, Fink MP, Visner MS. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-α in conscious dogs. J Clin Invest 1992;90:389-98.
17. Mann DL, Young JB. Basic mechanisms in congestive heart failure. Recognizing the role of the proinflammatory cytokines. Chest 1994;105:897-904.
18. Olsson I, Gatanaga T, Gullberg U, Lantz M, Granger GA. Tumor necrosis factor (TNF) binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy. Eur Cytokine Netw 1993;4:169-180.
19. Aderka D, Engelmann M, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactiviiy of tumour necrosis factor by its soluble receptors. J Exp Med 1992;175:323-9.
20. Hirano T, Interleukin 6. In: Thompson A, ed. The Cytokine Handbook. Boston: Academic Press, 1991: 169-90.
21. Miyao Y, Yasue H, Ogawa H et al. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J 1993;126:1299-1304.
22. Tsutamoto T, Hisanaga T, Wada A, Maeda Y, Fukai D. Plasma concentration of interleukin-6 as a marker of prognosis in patients with chronic congestive heart failure (abstract). Circulation 1994;90:I-381.
23. Pye M, Rae AP, Cobbe SM. Study of serum C-reaclive protein concentration in cardiac failure. Br Heart J 1990;63:228-230.
24. Abbas AK, Lichtman AH, Pober JS. Cytokines. In: Abbas AK, Lichtman AH, Pober JS, eds. Cellular and Molecular Immunology. Philadelphia: WB Saunders, 1991: 225-43.
25. Bagglioni M. Novel aspects of inflammation: interleukin-8 and related chemotactic cytokines. Clin Invest 1993;71:812-14.
26. Wiedermann CJ, Beimpold H, Herold M, Knapp E, Braunsteiner H. Increased levels of serum neopterin and decreased production if neutrophil Superoxide anions in chronic heart failure with increased levels of tumor necrosis factor-alpha. J Am Coll Cardiol 1993;22:1897-901.
27. Feldman AM, Bristow MR. Parmley WW et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993;329:149-55.
28. Matsumori A, Shioi T, Yamada T, Matsui S, Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 1994;89:955-8.